Sweden · Delayed Price · Currency is SEK Nanologica AB Statistics
Total Valuation
Nanologica AB has a market cap or net worth of SEK 99.95 million. The enterprise value is 134.52 million.
| Market Cap | 99.95M |
| Enterprise Value | 134.52M |
Important Dates
The last earnings date was Monday, August 31, 2026.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nanologica AB has 328.77 million shares outstanding. The number of shares has increased by 181.26% in one year.
| Current Share Class | 328.77M |
| Shares Outstanding | 328.77M |
| Shares Change (YoY) | +181.26% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 3.72% |
| Float | 244.61M |
Valuation Ratios
The trailing PE ratio is 3.15 and the forward PE ratio is 15.20.
| PE Ratio | 3.15 |
| Forward PE | 15.20 |
| PS Ratio | 0.77 |
| PB Ratio | 0.64 |
| P/TBV Ratio | 0.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 7.16 |
| EV / Sales | 1.04 |
| EV / EBITDA | 5.06 |
| EV / EBIT | 8.47 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.84, with a Debt / Equity ratio of 0.34.
| Current Ratio | 2.84 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 2.02 |
| Debt / FCF | -0.92 |
| Interest Coverage | 4.56 |
Financial Efficiency
Return on equity (ROE) is 18.07% and return on invested capital (ROIC) is 6.38%.
| Return on Equity (ROE) | 18.07% |
| Return on Assets (ROA) | 5.57% |
| Return on Invested Capital (ROIC) | 6.38% |
| Return on Capital Employed (ROCE) | 7.96% |
| Weighted Average Cost of Capital (WACC) | 4.22% |
| Revenue Per Employee | 1.80M |
| Profits Per Employee | 260,972 |
| Employee Count | 72 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 0.39 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.13% in the last 52 weeks. The beta is -0.09, so Nanologica AB's price volatility has been lower than the market average.
| Beta (5Y) | -0.09 |
| 52-Week Price Change | -74.13% |
| 50-Day Moving Average | 0.41 |
| 200-Day Moving Average | 0.51 |
| Relative Strength Index (RSI) | 30.02 |
| Average Volume (20 Days) | 950,071 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nanologica AB had revenue of SEK 129.48 million and earned 18.79 million in profits. Earnings per share was 0.10.
| Revenue | 129.48M |
| Gross Profit | 113.07M |
| Operating Income | 15.89M |
| Pretax Income | 18.79M |
| Net Income | 18.79M |
| EBITDA | 22.13M |
| EBIT | 15.89M |
| Earnings Per Share (EPS) | 0.10 |
Balance Sheet
The company has 19.06 million in cash and 53.63 million in debt, with a net cash position of -34.57 million or -0.11 per share.
| Cash & Cash Equivalents | 19.06M |
| Total Debt | 53.63M |
| Net Cash | -34.57M |
| Net Cash Per Share | -0.11 |
| Equity (Book Value) | 156.43M |
| Book Value Per Share | 0.48 |
| Working Capital | 81.09M |
Cash Flow
In the last 12 months, operating cash flow was -56.84 million and capital expenditures -1.55 million, giving a free cash flow of -58.38 million.
| Operating Cash Flow | -56.84M |
| Capital Expenditures | -1.55M |
| Depreciation & Amortization | 6.25M |
| Net Borrowing | -54.96M |
| Free Cash Flow | -58.38M |
| FCF Per Share | -0.18 |
Margins
Gross margin is 87.33%, with operating and profit margins of 12.27% and 14.51%.
| Gross Margin | 87.33% |
| Operating Margin | 12.27% |
| Pretax Margin | 14.51% |
| Profit Margin | 14.51% |
| EBITDA Margin | 17.09% |
| EBIT Margin | 12.27% |
| FCF Margin | n/a |
Dividends & Yields
Nanologica AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -181.26% |
| Shareholder Yield | -181.26% |
| Earnings Yield | 18.80% |
| FCF Yield | -58.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nanologica AB has an Altman Z-Score of -0.28 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.28 |
| Piotroski F-Score | 4 |